ABSI
$3.03
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
Intraday
Recent News
Absci Highlights AI Antibody Platform, ABS-201 Hair-Loss Trial Milestones at Leerink Conference
Absci (NASDAQ:ABSI) used a presentation at the Leerink Partners Global Healthcare Conference to outline how the company is applying its internal AI-driven drug design platform to generate “differentiated” antibody assets, while advancing its own lead clinical program, ABS-201, in androgenetic alopec
Absci Conference: Agentic AI Push and ABS-201 Hair-Loss Program Take Center Stage
Executives from Absci (NASDAQ:ABSI) used a conference presentation to emphasize the company’s focus on building clinical-stage drug assets using artificial intelligence, with management repeatedly framing long-term value creation around programs that advance into and through the clinic rather than s
Absci Corporation's (NASDAQ:ABSI) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures
Key Insights Significantly high institutional ownership implies Absci's stock price is sensitive to their trading...
Absci Unveils Origin-1 AI Model, Teases 2025 Hair-Loss Data and Q4 Endometriosis Trial Launch
Absci (NASDAQ:ABSI) used a presentation at the 44th JPMorgan Healthcare Conference to outline recent platform updates and provide a timeline for upcoming clinical data in androgenic alopecia and endometriosis. Founder and CEO Sean McClain said the company is “entering this really exciting new era” i
Analysts Cut Absci (ABSI) Target, Spotlight New Alopecia Therapy in Early Trials
Absci Corporation (NASDAQ:ABSI) is one of the best penny stocks to buy in 2026. On January 8, Morgan Stanley downgraded Absci Corporation (NASDAQ:ABSI) to Equalweight from Overweight and cut its price target to $4.32 from $5.80, citing higher risk and limited near-term visibility following the company’s third-quarter update. Interim Phase 1 data for ABS-101, Absci’s […]